CHRS

SEC source: 0001567619-22-003502 · doc1.xml · derivative · entry 1

Wahlstrom Mats · CIK 0001459154 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-01-07

F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-003508 · doc1.xml · derivative · entry 1

STOLPER MARK · CIK 0001281961 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-01-07

F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-003511 · doc1.xml · derivative · entry 1

HEALY JAMES · CIK 0001245624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-01-07

F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-003505 · doc1.xml · derivative · entry 1

TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2032-01-07

F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.

F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-000820 · doc1.xml · derivative · entry 2

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-01-04

F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-000820 · doc1.xml · nonDerivative · entry 1

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,138

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 60,000 RSUs.

F3 · balance_after: Includes 1,527 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan.

SEC source: 0001567619-22-000819 · doc1.xml · derivative · entry 2

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2032-01-04

F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-000819 · doc1.xml · nonDerivative · entry 1

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,154

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 112,083 RSUs.

F3 · balance_after: Includes 1,768 shares acquired on November 15, 2021, pursuant to Issuer's employee stock purchase plan.

SEC source: 0001567619-22-000821 · doc1.xml · derivative · entry 4

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402,500

Underlying: Common Stock · 402,500 shares

Expires 2032-01-04

F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 4, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-22-000821 · doc1.xml · nonDerivative · entry 1

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 579,508

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3 of the RSUs vest annually on January 4 of each year, with the first 1/3 vesting on January 4, 2023 and with the RSUs being fully vested on January 4, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 86,250 RSUs.

SEC source: 0001567619-21-021059 · doc1.xml · nonDerivative · entry 1

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 436,684

F1 · kind: Gift for charitable purposes of 10,000 shares of the Company's Common Stock to a private trust. The private trust is not owned or controlled by the Reporting Person or the Reporting Person's family members and no compensation was received in return for the gift of the shares.

F2 · ownership.nature: These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.

SEC source: 0001567619-21-018470 · doc1.xml · nonDerivative · entry 1

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,611

F1 · kind: Represents shares automatically sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").

F2 · balance_after: Includes 20,000 RSUs.

SEC source: 0001104659-21-120896 · tm2128862d1_4.xml · nonDerivative · entry 3

HEALY JAMES · CIK 0001245624 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.905, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC.

SEC source: 0001104659-21-120896 · tm2128862d1_4.xml · nonDerivative · entry 2

HEALY JAMES · CIK 0001245624 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 286,076

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.43, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

F2 · ownership.nature: The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC.

SEC source: 0001104659-21-120896 · tm2128862d1_4.xml · nonDerivative · entry 1

HEALY JAMES · CIK 0001245624 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 334,405

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.17, inclusive. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The shares are held by Sofinnova Management VII, LLC. The Reporting Person is the managing member of Sofinnova Management VII, LLC. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his proportionate pecuniary interest in Sofinnova Management VII, LLC.

SEC source: 0001567619-21-013149 · doc1.xml · derivative · entry 2

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2031-07-06

F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/24th of the total number of shares subject to the option in successive, equal monthly installments measured from July 6, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-013149 · doc1.xml · nonDerivative · entry 1

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,790

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on July 6 of each year, with the first 1/2 vesting on July 6, 2022 and with the RSUs being fully vested on July 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 122,083 RSUs and 1,388 shares of Common Stock purchased under Issuer's Employee Stock Purchase Plan on May 14, 2021 in a transaction exempt from Section 16(b) under Rule 16b3(c).

SEC source: 0001567619-21-011972 · doc1.xml · nonDerivative · entry 1

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,118

F1 · price: The transaction was executed in multiple trades in prices ranging from $13.415 to $13.4294, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F2 · balance_after: Includes 30,000 restricted stock units.

F3 · balance_after: Includes 1,418 shares acquired on May 14, 2021, pursuant to Issuer's employee stock purchase plan.

SEC source: 0001567619-21-011842 · doc1.xml · derivative · entry 7

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 31,054 shares

Expires 2021-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof.

SEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 3

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 493,258

F3 · price: The transaction was executed in multiple trades in prices ranging from $13.55 to $13.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 2

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 524,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011842 · doc1.xml · derivative · entry 6

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,054

Underlying: Common Stock · 300,000 shares

Expires 2021-07-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The shares underlying this option are fully vested and exercisable as of the date hereof.

SEC source: 0001567619-21-011842 · doc1.xml · nonDerivative · entry 1

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 493,258

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-011153 · doc1.xml · derivative · entry 1

MENDELSON ALAN C · CIK 0001073381 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-05-21

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 21, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-011154 · doc1.xml · derivative · entry 1

STOLPER MARK · CIK 0001281961 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2031-05-21

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 21, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-008804 · doc1.xml · derivative · entry 2

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-04-28

F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 8, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-008804 · doc1.xml · nonDerivative · entry 1

Stilwell McDavid · CIK 0001851389 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on April 1 of each year, with the first 1/2 vesting on April 1, 2022 and with the RSUs being fully vested on April 1, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 30,000 RSUs.

SEC source: 0001567619-21-008803 · doc1.xml · nonDerivative · entry 1

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,386

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on April 1 of each year, with the first 1/2 vesting on April 1, 2022 and with the RSUs being fully vested on April 1, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 72,083 RSUs.

SEC source: 0001567619-21-008805 · doc1.xml · nonDerivative · entry 1

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,402

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/2 of the RSUs vest annually on April 1 of each year, with the first 1/2 vesting on April 1, 2022 and with the RSUs being fully vested on April 1, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

F2 · balance_after: Includes 72,083 RSUs.

SEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 7

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,188

Underlying: Common Stock · 57,812 shares

Expires 2028-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 6

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,688

Underlying: Common Stock · 20,312 shares

Expires 2027-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-006128 · doc1.xml · derivative · entry 5

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,356 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof.

SEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 4

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,386

F2 · price: The transaction was executed in multiple trades at prices ranging from $16.071 to $16.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 3

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,626

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 2

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,814

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-006128 · doc1.xml · nonDerivative · entry 1

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,502

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-005917 · doc1.xml · derivative · entry 4

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,688

Underlying: Common Stock · 20,312 shares

Expires 2027-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-005917 · doc1.xml · nonDerivative · entry 3

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,402

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-005917 · doc1.xml · nonDerivative · entry 2

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,739

F2 · price: The transaction was executed in multiple trades in prices ranging from $15.45 to $15.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-005917 · doc1.xml · nonDerivative · entry 1

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,051

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-004508 · doc1.xml · derivative · entry 3

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,488 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: All of the shares underlying this option are vested and exercisable as of the date hereof.

SEC source: 0001567619-21-004508 · doc1.xml · nonDerivative · entry 2

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,739

F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person.

F3 · price: The transaction was executed in multiple trades in prices ranging from $17.19 to $17.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-004508 · doc1.xml · nonDerivative · entry 1

Anicetti Vincent R · CIK 0001733375 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,227

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-002144 · doc1.xml · derivative · entry 1

Vexler Vladimir · CIK 0001759506 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-02-01

F1 · derivative.exercise_date: On January 22, 2021, the compensation committee of the board of directors of Coherus BioSciences, Inc. approved the grant of an option to purchase 50,000 shares of common stock subject to the achievement of a certain performance milestone. 100% of the shares underlying this option were fully vested and exercisable at grant.

SEC source: 0001567619-21-002141 · doc1.xml · derivative · entry 3

Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,167

Underlying: Common Stock · 7,402 shares

Expires 2028-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-002141 · doc1.xml · nonDerivative · entry 2

Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,295

F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.

F2 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-002141 · doc1.xml · nonDerivative · entry 1

Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 52,083 restricted stock units.

SEC source: 0001567619-21-002142 · doc1.xml · derivative · entry 1

Lanfear Dennis M · CIK 0001420822 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2031-02-01

F1 · derivative.exercise_date: On January 23, 2021, the board of directors of Coherus BioSciences, Inc. approved the grant of an option to purchase 125,000 shares of common stock subject to the achievement of a certain performance milestone. 100% of the shares underlying this option were fully vested and exercisable at grant.

SEC source: 0001567619-21-001600 · doc1.xml · derivative · entry 4

Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,569

Underlying: Common Stock · 40,000 shares

Expires 2028-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0001567619-21-001600 · doc1.xml · nonDerivative · entry 3

Viret Jean-Frederic · CIK 0001427569 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,295

F1 · kind: The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.

F2 · balance_after: Includes 52,083 restricted stock units.